High efficiency microfluidic device for large scale engineered cell therapy manufacturing

用于大规模工程细胞治疗制造的高效微流体装置

基本信息

  • 批准号:
    10693775
  • 负责人:
  • 金额:
    $ 29.59万
  • 依托单位:
  • 依托单位国家:
    美国
  • 项目类别:
  • 财政年份:
    2023
  • 资助国家:
    美国
  • 起止时间:
    2023-09-06 至 2024-09-05
  • 项目状态:
    已结题

项目摘要

The goal of this project is to demonstrate the feasibility of a gentle and high-yield microfluidic device for the enrichment and capture of CD3+ T cells, for use in manufacturing autologous and allogenic engineered cell therapies. Despite impressive clinical results CAR-T and other engineered cell therapies, manufacturing these products is time consuming and costly. The ideal solution is one that could process whole blood, including target cell enrichment and genetic engineering, with minimal human intervention. Indee. Inc. previously developed Hydropore™, a microfluidic technology that has been optimized for the delivery of genes and constructs to immune cells (e.g., T-cells). Hydropore™ is a reliable and rapid alternative to current transfection approaches that yields tens to hundreds of millions of high-quality engineered cells negligible impact on cell viability and function. However, immune cells must be isolated and enriched from whole blood prior to transfection, a cumbersome, multistep process that introduces variability in the final cell product. Therefore, the Phase I objective is to develop a microfluidic device that is similarly optimized for T cell isolation and enrichment. Studies will focus on (1) the design and qualification of prototype device that is compatible with the Hydropore instrument, (2) device optimization to maximize the viability and yield of isolated cells, and (3) demonstrating the performance of the optimized T cell capture device in improving the quality and yield of engineered T cells. The success of this project will demonstrate the feasibility of a high-yield T cell enrichment device that will not only improve the source material for cellular immunotherapies but also make the manufacturing process more robust and reliable, and ultimately providing more potent and cost-effective therapies that will benefit more patients.
本项目的目标是证明一个温和的和高产量的微流控装置的可行性, 用于制备自体和同种异体工程化细胞的CD 3 + T细胞的富集和捕获 治疗尽管CAR-T和其他工程细胞疗法的临床结果令人印象深刻,但制造这些细胞仍然是一个挑战。 产品既费时又费钱。理想的解决方案是可以处理全血(包括目标)的解决方案 细胞富集和基因工程,以最少的人为干预。没错Inc.以前开发 Hydropore™是一种微流控技术,已优化用于将基因和构建体递送至 免疫细胞(例如,T细胞)。Hydropore™是目前转染方法的可靠和快速替代方法 这会产生数千万至数亿个高质量的工程细胞,对细胞活力的影响可以忽略不计, 功能然而,在转染前必须从全血中分离和富集免疫细胞, 繁琐的多步骤过程,这在最终的细胞产品中引入了可变性。因此,第一阶段 本发明的目的是开发一种微流控装置,其类似地优化用于T细胞分离和富集。研究 将重点关注(1)与Hydropore仪器兼容的原型器械的设计和鉴定, (2)装置优化,以最大化分离细胞的活力和产量,以及(3)证明性能 优化的T细胞捕获装置在提高工程化T细胞的质量和产量方面的作用。的成功 该项目将证明高产量T细胞富集装置的可行性,该装置不仅可以提高 细胞免疫疗法的源材料,而且还使制造过程更稳健和可靠, 并最终提供更有效和更具成本效益的疗法,使更多患者受益。

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

Ryan Pawell其他文献

Ryan Pawell的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('Ryan Pawell', 18)}}的其他基金

Rapid, single-step precision engineering and pre-clinical evaluation of chimeric antigen receptor Regulatory T cells for Type 1 diabetes
嵌合抗原受体调节性 T 细胞治疗 1 型糖尿病的快速、单步精密工程和临床前评估
  • 批准号:
    10477106
  • 财政年份:
    2022
  • 资助金额:
    $ 29.59万
  • 项目类别:

相似海外基金

HLA-homozygous iPSC-cardiomyocytE Aggregate manufacturing technoLogies for allogenic cell therapy to the heart (HEAL)
HLA-纯合 iPSC-心肌细胞 用于心脏同种异体细胞治疗 (HEAL) 的聚集体制造技术
  • 批准号:
    10039902
  • 财政年份:
    2022
  • 资助金额:
    $ 29.59万
  • 项目类别:
    EU-Funded
Evaluation of the efficacy of LAT1 inhibitor to tumor stroma and immunity in an allogenic mouse model of colon cancer having abundant stroma.
在具有丰富基质的同种异体结肠癌小鼠模型中评估 LAT1 抑制剂对肿瘤基质和免疫的功效。
  • 批准号:
    21K15925
  • 财政年份:
    2021
  • 资助金额:
    $ 29.59万
  • 项目类别:
    Grant-in-Aid for Early-Career Scientists
Mechanism of kidney injury associated with graft-versus-host disease after allogenic stem cell transplantation
同种异体干细胞移植后移植物抗宿主病相关肾损伤的机制
  • 批准号:
    21K08410
  • 财政年份:
    2021
  • 资助金额:
    $ 29.59万
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)
Clarification of the origin and maintenance mechanisms of junctional epithelium and identification of its stem cells using allogenic tooth germ transplantation
阐明交界上皮的起源和维持机制并利用同种异体牙胚移植鉴定其干细胞
  • 批准号:
    20K21672
  • 财政年份:
    2020
  • 资助金额:
    $ 29.59万
  • 项目类别:
    Grant-in-Aid for Challenging Research (Exploratory)
The study about the allogenic MSCs transplantation to the cardiac disease models.
同种异体间充质干细胞移植至心脏病模型的研究。
  • 批准号:
    18K16395
  • 财政年份:
    2018
  • 资助金额:
    $ 29.59万
  • 项目类别:
    Grant-in-Aid for Early-Career Scientists
Artificial nerves containing allogenic basal lamellae scaffold and bone marrow derived stem cells
含有同种异体基底板层支架和骨髓干细胞的人工神经
  • 批准号:
    17K10951
  • 财政年份:
    2017
  • 资助金额:
    $ 29.59万
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)
Role of HSP90-alpha in preserving immunoprivilege of allogenic mesenchymal stem cells in the ischemic heart
HSP90-α 在保护缺血心脏同种异体间充质干细胞免疫特权中的作用
  • 批准号:
    370541
  • 财政年份:
    2017
  • 资助金额:
    $ 29.59万
  • 项目类别:
    Operating Grants
Attempt to Prefabricate Vascularized Allogenic Bone in Recipient -Use of Cultured Bone Marrow Cells-
尝试在受者体内预制血管化的同种异体骨 - 使用培养的骨髓细胞 -
  • 批准号:
    16K10863
  • 财政年份:
    2016
  • 资助金额:
    $ 29.59万
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)
Allogenic micobiota-reconstitution (AMR) for the treatment of patients with diarhea-predominant irritable bowel syndrome (IBS-D) - the AMIRA trial
同种异体微生物群重建 (AMR) 用于治疗腹泻型肠易激综合征 (IBS-D) 患者 - AMIRA 试验
  • 批准号:
    276706135
  • 财政年份:
    2015
  • 资助金额:
    $ 29.59万
  • 项目类别:
    Clinical Trials
Induction of thyme epithelial cells from iPS cells and application to allogenic transplantation
iPS细胞诱导百里香上皮细胞及其在同种异体移植中的应用
  • 批准号:
    15H04915
  • 财政年份:
    2015
  • 资助金额:
    $ 29.59万
  • 项目类别:
    Grant-in-Aid for Scientific Research (B)
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了